Please login to the form below

Not currently logged in
Email:
Password:

rosuvastatin

This page shows the latest rosuvastatin news and features for those working in and with pharma, biotech and healthcare.

Better times ahead, promises AZ as Crestor drop outweighs new drugs

Better times ahead, promises AZ as Crestor drop outweighs new drugs

Crestor (rosuvastatin) continued its inexorable decline, down another 42% to $389m in the three-month period as generic competition continued to take its toll, particularly in the EU and Japan.

Latest news

More from news
Approximately 5 fully matching, plus 64 partially matching documents found.

Latest appointments

  • Evan Lippman joins Aileron Therapeutics Evan Lippman joins Aileron Therapeutics

    Highlights of his career include a spell as executive director at AstraZeneca where he led on huge brands such as Crestor (rosuvastatin calcium) and Nexium (esomeprazole) and heading US business development

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Swordfish Advertising

At Swordfish Advertising, we believe building an effective brand shouldn't be stressful. Don't get us wrong; it takes blood, sweat...

Latest intelligence

Developing advocacy in the pharmaceutical industry.
The importance of advocacy programmes...
GDPR and events. What does the pharma industry need to know?
Many people in the pharma industry still aren’t following the rules set out by the GDPR when it comes to running events and attending tradeshows. But with eye-watering fines for...
Digital trends in B2B sales - how far behind is Pharma?
The modern approach to B2B sales is data-driven, and enabled by digital tools....

Infographics